Cat. No. 3716
Alternative Name: NSC 680410
Chemical Name: 4-[[(2,5-Dihydroxyphenyl)methyl]ami
Biological Activityp210bcr/abl tyrosine kinase inhibitor (IC50 = 14 μM). Induces apoptosis in T-lymphoblastic human leukemia cell lines (IC50 values range from 16.8 to 216.3 nM) in vitro. Displays selectivity for chronic myelogenous leukemia (CML) myeloid progenitors in vitro.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Avramis et al (2002) In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines. Cancer Chemother.Pharmacol. 50 479. PMID: 12451475.
Mow et al (2002) Effects of bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99 664. PMID: 11781252.
Svingen et al (2000) Effects of the bcl/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin.Cancer Res. 6 237. PMID: 10656455.
If you know of a relevant reference for Adaphostin please let us know.
Citations are publications that use Tocris products. Selected citations for Adaphostin include:
Xia et al (2014) EZH2 silencing with RNA interference induces G2/M arrest in human lung cancer cells in vitro. Biomed Res Int 2014 348728. PMID: 24745014.
Do you know of a great paper that uses Adaphostin from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Adaphostin, supplier, p210bcr/abl, kinases, inhibitors, inhibits, chronic, myelogenous, leukaemia, leukemia, CML, NSC680410, Tocris Bioscience, Abl Kinase Inhibitor products
Find multiple products by catalog number
New Products in this Area
ATP-competitive inhibitor of DAPK and ZIPKst-Ht31 P
Negative control for st-Ht31 (Cat. No. 6286)st-Ht31
Inhibits PKA/AKAP interactions; cell permeableP21d hydrochloride
Potent and selective Brk inhibitorCVT 313
High affinity PKC activator; also APP modulatorJH 295
Irreversible Nek2 inhibitorOXSI 2
Potent Syk kinase inhibitor; also inhibits assembly of NLRP3 inflammasomesSTK16-IN-1
Serine/threonine protein kinase 16 (STK16) inhibitor; also inhibits PI 3Kδ, PI 3Kγ and mTOR kinases.AZ PFKFB3 26
Potent and selective PFKFB3 inhibitorNCL 00017509
Potent and reversible NIMA related kinase 2 (Nek2) inhibitorXMD 8-87
Potent Ack1/TNK2 inhibitorSKI 178
Non-lipid sphingosine kinase 1 (SphK1) inhibitorML 315 hydrochloride
Inhibitor of Clk and DYRK kinasesEverolimus
mTOR inhibitor;immunosuppressantPKI (5-24)
High affinity PKA inhibitorTDZD 8
Selective non-ATP competitive inhibitor of GSK 3βBI 605906
Selective IKKβ inhibitorGSK 319347A
Potent and selective IKKε inhibitorFRAX 597
Potent group I PAK inhibitorMRT 68921 dihydrochloride
Potent ULK inhibitor; inhibits autophagyAM 2394
Potent glucokinase activator; orally bioavailableeCF 309
Potent mTOR inhibitorPF 3758309 dihydrochloride
Potent PAK4 inhibitor; orally availableAZ Dyrk1B 33
Potent and selective Dyrk1B kinase inhibitor
November 8 - 10, 2017